Sonoma Pharmaceuticals, Inc. (SNOA) shares Skyrockets Amid Its OTC Launch on Amazon

Sonoma Pharmaceuticals, Inc. (SNOA) stock made a swift move as the buying volume increased following the Amazon.com business announcement. In the pre-market on September 28, 2021, SNOA stock had already soared above 70%.

The global healthcare leader in stabilized hypochlorous acid (HOCl) products, Sonoma Pharmaceuticals, Inc. (SNOA) intends to invest in Amazon’s e-commerce business. The company will make an over-the-counter (OTC) consumer launch on Amazon.com in the United States and Europe.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Investors have really appreciated the development of SNOA. Entering the e-commerce business means that Sonoma has taken a competitive advantage as they consider it a potential market. Sonoma Pharmaceuticals has decided that it will launch Regenacyn® Advanced Scar Gel and Ocucyn® Eyelid & Eyelash Cleanser on Amazon.com, in the U.S. While the company will launch MucoClyns™ on Amazon sites in Europe.

It will be easier for the customers to access these products and order online in no time. All three products are based on Sonoma’s patented Microcyn® technology. The customers can order their product now.

Regenacyn® Advanced Scar Gel is available for $24.99 per ounce and Ocucyn® Eyelid & Eyelash Cleanser is available soon. Whereas, MucoClyns™ is available at Amazon UK, Germany, France, Italy, and Spain.

All three products are Sonoma’s superior, safe and effective hypochlorous acid products. In the past, the company has been selling its products in the conventional manner available as a prescription or for physicians only. The OTC launch will allow SNOA’s products marketed directly to consumers.

Apart from this, we can see that Sonoma’s Microcyn® technology is a proven channel of the company and is widely available for everyone – now. Regenacyn Advanced Scar Gel is a clinically proven product with positive impacts. It helps in improving the scares and reduces pain and inflammation. The gel protects the patient’s wound and moisturizes the area of impact.

The second product available in the US market is Ocucyn Eyelid & Eyelash Cleanser. This product is for everyday use and is effective for the good eyelid. It is a steroid-free, non-irritating cleaner that requires no special handling.

The last product to be launched on the OTC is MucoClyns, a personal decontamination solution for the face and skin. It is effective against burns, cuts, mucous membranes and treats immediately after unexpected exposure to infection risk.

This shows that all the products are simple and for use in daily life. Sonoma Pharmaceuticals’ OTC launch on Amazon will increase the demand for their products and could be a significant source of sales for the company.

The CEO of Sonoma Pharmaceuticals, Amy Trombly said that they are excited to make their products directly available to consumers via Amazon. This provides them with an opportunity to reach a wider audience and offer its clinically proven and patented Microcyn® Technology. Sonoma Pharmaceuticals (SNOA) going into the e-commerce race will be a significant move for the company in the long term.